Moderna's stock gains 3% as it moves forward with Phase 3 clinical trial for RSV vaccine candidate
Shares of Moderna Inc. gained 3.0% in trading on Tuesday after the company said it began a Phase 3 clinical trial evaluating its respiratory syncytial virus vaccine candidate. RSV is a common, seasonal respiratory virus that causes cold symptoms; it is more likely to become serious in children and older adults. The study is expected to test the experimental vaccine in about 34,000 adults who are at least 60 years old. "Our ultimate goal is to combine our RSV vaccine with our COVID-19 and flu boosters into a single-dose booster," Moderna CEO Stéphane Bancel said in a news release. Moderna's stock is down 6.0% over the past year, while the broader S&P 500 has gained 11.1%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.